Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges

Author(s):Show less -

Pais, Marcos ^[1] ; Martinez, Luana ^[1] ; Ribeiro, Octavio ^[1] ; Loureiro, Julia ^[1] ; Fernandez, Romel ^[1] ; Valiengo, Leandro ^[1] ; Canineu, Paulo ^{[1, 2]} ; Stella, Florindo ^{[3, 1]} ; Talib, Leda ^[1] ; Radanovic, Marcia ^[1] ; Forlenza, V, Orestes

Affiliation

^[1] V, Univ Sao Paulo HCFMUSP, Fac Med, Hosp Clin, Lab Neurociencias LIM27, Dept & Inst Psiquiatria, Sao Paulo, SP - Brazil

^[2] Pontificia Univ Catolica Sao Paulo PUC SP, Programa Gerontol, Sao Paulo, SP - Brazil

^[3] Univ Estadual Paulista UNESP, Inst Biociencias, Rio Claro, SP - Brazil

• Document type: Journal article
• Source: Revista Brasileira de Psiquiatria; v. 42, n. 4, p. 431-441, JUL-AUG 2020.
• Web of Science Citations: 3

Abstract

The prevalence of Alzheimer's disease (AD), a progressive neurodegenerative disorder, is expected to more than double by 2050. Studies on the pathophysiology of AD have been changing our understanding of this disorder and setting a new scenario for drug development and other therapies. Concepts like the ``amyloid cascade{''} and the ``continuum of AD,{''} discussed in this article, are now well established. From updated classifications and recommendations to advances in biomarkers of AD, we aim to critically assess the literature on AD, addressing new definitions and challenges that emerged from recent studies on the subject. Updates on the status of major clinical trials are also given, and future perspectives are discussed. (AU)

• FAPESP's process: 14/50873-3 - INCT 2014: National Institute of Biomarkers in Neuropsychiatry
• Grantee: Wagner Farid Gattaz
• Support Opportunities: Research Projects - Thematic Grants